APA (7th ed.) Citation

E, A., H, K., D, T., I, B., G, B., & S, V. (2010). Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clinical lymphoma, myeloma & leukemia, 10(4), 281. https://doi.org/10.3816/CLML.2010.n.058

Chicago Style (17th ed.) Citation

E, Apostolidou, Kantarjian H, Thomas D, Burger I, Borthakur G, and Verstovsek S. "Phase II Study of Sunitinib in Patients with Primary or Post-polycythemia Vera/essential Thrombocythemia Myelofibrosis." Clinical Lymphoma, Myeloma & Leukemia 10, no. 4 (2010): 281. https://doi.org/10.3816/CLML.2010.n.058.

MLA (9th ed.) Citation

E, Apostolidou, et al. "Phase II Study of Sunitinib in Patients with Primary or Post-polycythemia Vera/essential Thrombocythemia Myelofibrosis." Clinical Lymphoma, Myeloma & Leukemia, vol. 10, no. 4, 2010, p. 281, https://doi.org/10.3816/CLML.2010.n.058.